KIMBERLY ESSER: Open Payments
NPI 1699187393 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$542 in 30 payments from 12 companies in 2025. Trend: 2023 $1,333 · 2024 $778 · 2025 $542
Food & beverage: $542
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $109 |
| Lilly USA, LLC | 6 | $105 |
| UCB, Inc. | 3 | $67 |
| Merck Sharp & Dohme LLC | 2 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Amgen Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Antares Pharma, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 2 | $20 |
Products named: MOUNJARO, UBRELVY, Fintepla, GARDASIL 9, XIFAXAN, EVENITY, CAPLYTA, QULIPTA.
Industry payments across MS — which companies pay providers there.
